TNFSF11 and head and neck squamous cell carcinoma: Similarly, TM also reduces the expression of nuclear factor-κB ligand (RANKL) in osteoblasts and osteocytes by inhibiting LOX activation, thereby reducing metastatic bone destruction due to head and neck squamous cell carcinoma (HNSCC) [126].